AXT107

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
Xconomy
Wed, 06/24/20 - 10:14 am
AsclepiX Therapeutics
eye disease
Eylea
Lucentis
macular edema
wet age-related macular degeneration
retinal occulsion
AXT107